LENZ Therapeutics (LENZ) Non-Current Assets (2020 - 2026)
LENZ Therapeutics (LENZ) reported Non-Current Assets of $4.2 million for Q1 2026, up 22.84% year-over-year from $3.4 million in Q1 2025, and down 6.63% on a QoQ basis from $4.5 million in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Non-Current Assets data on file, last reported at $4.2 million in Q1 2026.
- Quarterly Non-Current Assets rose 22.84% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.1 million (up 20.17% YoY) and the FY2025 annual result came in at $4.5 million, up 31.8% from the prior year.
- Non-Current Assets eased to $4.2 million in Q1 2026 per LENZ's latest filing, from $4.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $46.5 million in Q4 2022 and bottomed at $648000.0 in Q1 2024.
- The 5-year median for Non-Current Assets is $4.2 million (2026), against an average of $16.5 million.
- The widest annual swing landed in 2022, when Non-Current Assets soared 1053.02%; it then plunged 98.37% in 2024.
- Tracing LENZ's Non-Current Assets over 5 years: stood at $46.5 million in 2022, then sank by 93.27% to $3.1 million in 2023, then grew by 8.14% to $3.4 million in 2024, then jumped by 31.8% to $4.5 million in 2025, then dropped by 6.63% to $4.2 million in 2026.
- Per Business Quant, the three latest LENZ Non-Current Assets figures stand at $4.2 million (Q1 2026), $4.5 million (Q4 2025), and $3.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | 4.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.17 Mn |
| Dec 31, 2025 | 4.46 Mn |
| Sep 30, 2025 | 3.71 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | 3.30 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Mar 31, 2024 | 648,000.00 |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 27.45 Mn |
| Jun 30, 2023 | 35.87 Mn |
| Mar 31, 2023 | 39.69 Mn |
| Dec 31, 2022 | 46.54 Mn |
| Sep 30, 2022 | 36.35 Mn |
| Jun 30, 2022 | 27.14 Mn |
| Mar 31, 2022 | 34.85 Mn |
| Dec 31, 2021 | 20.25 Mn |
| Sep 30, 2021 | 14.92 Mn |
| Jun 30, 2021 | 2.35 Mn |
| Dec 31, 2020 | 1.46 Mn |